Login to Your Account



Clinic Roundup


Thursday, January 19, 2012
• Rexahn Pharmaceuticals Inc., of Rockville, Md., received approval from the Hungarian Regulatory Authority and Ethics Committee for its initial clinical trial application to begin a Phase I trial of RX-3117. Preclinical studies showed anticancer activity. The company plans to explore its potential in a broad range of cancers including colon, lung and pancreatic.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription